Correction to: Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal (PharmacoEconomics, (2022), 40, 5, (509-518), 10.1007/s40273-021-01098-3)

Abstract

The following sentence has been added to the end of the abstract of the original online version “This decision was subsequently appealed, and an appeal decision has been reached.” In the article, Sect. 3.2 Critique of Clinical Effectiveness Evidence and Interpretation, 5th para, 3rd and 4th sentences should be read as “For example, the company did not provide a description of the methods used for the matching, except the process of selection of variables for which adjustment is required. Based on the provided information, it appeared that data were available for only three of the variables (disease type, number of prior systemic therapies, type of prior systemic therapies) that were considered in the analysis of the HES data and only one variable (disease type) was chosen for matching.” In the article, Sect. 3.3 Cost‑Effectiveness Evidence Submitted by the Company, 14th para, final sentence should be removed. “The impact of AEs on HRQoL was, however, not included in the model.” The original article has been corrected.